Literature DB >> 33057949

Relationship Between Genetic Variants of ACAT1 and APOE with the Susceptibility to Dementia (SADEM Study).

Jessica Sarahi Alavez-Rubio1, Nancy Martínez-Rodríguez2, Jorge Escobedo-de-la-Peña3, Osvaldo Garrido-Acosta4, Teresa Juárez-Cedillo5,6.   

Abstract

One of the hypotheses that have emerged to explain the origin of dementia relates the disease with altered lipid metabolism, particularly cholesterol. To maintain cholesterol homeostasis, the ACAT1 enzyme has an important function to regulate the production of Aβ. Moreover, APOE is the main cholesterol carrier in the brain, and it has been reported as a risk factor for this disease. This study evaluates the relationship between ACAT1 and APOE genetic variants with susceptibility for the development of Alzheimer's disease and other dementias. We examined four ACAT1 polymorphisms (rs2247071, rs2862616, rs3753526, rs1044925) and two in the APOE gene (rs7412, rs429358) in a group of 204 controls and 196 cases of dementia. Our results show one protective haplotype: CGCA (OR = 0.34, 95% CI = 0.23-0.46; p < 0.001) and one risk haplotype: CGGA (OR = 1.87, 95% CI = 1.34-2.60; p < 0.001) for the development of dementia. Subjects identified as APOE-ε4 allele carriers had a higher risk of developing dementia compared with non-carriers, OR = 13.33 (95% CI = 3.14-56.31). The results support the hypothesis that the ACAT1 gene, together with the APOE gene, plays an important role in susceptibility to the development of dementia and shows genetic characteristics of the Mexican population that can be used to identify the population at risk.

Entities:  

Keywords:  ACAT1; APOE; Cholesterol; Dementia; Polymorphism

Year:  2020        PMID: 33057949     DOI: 10.1007/s12035-020-02162-3

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  28 in total

1.  The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice.

Authors:  Henri J Huttunen; Daniel Havas; Camilla Peach; Cory Barren; Stephan Duller; Weiming Xia; Matthew P Frosch; Birgit Hutter-Paier; Manfred Windisch; Dora M Kovacs
Journal:  J Neuropathol Exp Neurol       Date:  2010-08       Impact factor: 3.685

Review 2.  Alzheimer's disease and cholesterol: the fat connection.

Authors:  Laura Canevari; John B Clark
Journal:  Neurochem Res       Date:  2006-12-27       Impact factor: 3.996

3.  Inhibiting ACAT1/SOAT1 in microglia stimulates autophagy-mediated lysosomal proteolysis and increases Aβ1-42 clearance.

Authors:  Yohei Shibuya; Catherine C Y Chang; Li-Hao Huang; Elena Y Bryleva; Ta-Yuan Chang
Journal:  J Neurosci       Date:  2014-10-22       Impact factor: 6.167

4.  Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model.

Authors:  L M Refolo; B Malester; J LaFrancois; T Bryant-Thomas; R Wang; G S Tint; K Sambamurti; K Duff; M A Pappolla
Journal:  Neurobiol Dis       Date:  2000-08       Impact factor: 5.996

5.  Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide.

Authors:  L Puglielli; G Konopka; E Pack-Chung; L A Ingano; O Berezovska; B T Hyman; T Y Chang; R E Tanzi; D M Kovacs
Journal:  Nat Cell Biol       Date:  2001-10       Impact factor: 28.824

6.  ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD.

Authors:  Elena Y Bryleva; Maximillian A Rogers; Catherine C Y Chang; Floyd Buen; Brent T Harris; Estelle Rousselet; Nabil G Seidah; Salvatore Oddo; Frank M LaFerla; Thomas A Spencer; William F Hickey; Ta-Yuan Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-26       Impact factor: 11.205

7.  Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway.

Authors:  Henri J Huttunen; Camilla Peach; Raja Bhattacharyya; Cory Barren; Warren Pettingell; Birgit Hutter-Paier; Manfred Windisch; Oksana Berezovska; Dora M Kovacs
Journal:  FASEB J       Date:  2009-07-22       Impact factor: 5.191

8.  The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease.

Authors:  Birgit Hutter-Paier; Henri J Huttunen; Luigi Puglielli; Christopher B Eckman; Doo Yeon Kim; Alexander Hofmeister; Robert D Moir; Sarah B Domnitz; Matthew P Frosch; Manfred Windisch; Dora M Kovacs
Journal:  Neuron       Date:  2004-10-14       Impact factor: 17.173

9.  Acat1 knockdown gene therapy decreases amyloid-β in a mouse model of Alzheimer's disease.

Authors:  Stephanie R Murphy; Catherine Cy Chang; Godwin Dogbevia; Elena Y Bryleva; Zachary Bowen; Mazahir T Hasan; Ta-Yuan Chang
Journal:  Mol Ther       Date:  2013-06-18       Impact factor: 11.454

10.  Knockdown of ACAT-1 reduces amyloidogenic processing of APP.

Authors:  Henri J Huttunen; Christopher Greco; Dora M Kovacs
Journal:  FEBS Lett       Date:  2007-03-30       Impact factor: 4.124

View more
  2 in total

1.  Cholesterol, Atherosclerosis, and APOE in Vascular Contributions to Cognitive Impairment and Dementia (VCID): Potential Mechanisms and Therapy.

Authors:  Michael Tran Duong; Ilya M Nasrallah; David A Wolk; Catherine C Y Chang; Ta-Yuan Chang
Journal:  Front Aging Neurosci       Date:  2021-03-25       Impact factor: 5.750

2.  Blocking cholesterol storage to treat Alzheimer's disease.

Authors:  Ta Yuan Chang; Catherine C Y Chang; Taylor C Harned; Adrianna L De La Torre; Junghoon Lee; Thao N Huynh; James G Gow
Journal:  Explor Neuroprotective Ther       Date:  2021-12-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.